(Q39005211)

8 September 2017

1 reference

title

Intraperitoneal immunotherapy: historical perspectives and modern therapy (English)

1 reference

8 September 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27834358%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

A Aggarwal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27834358%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

P Love

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27834358%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

S D Richard

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27834358%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

J Esquivel

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27834358%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

W B Bowne

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27834358%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

11 November 2016

1 reference

8 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27834358%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27834358%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27834358%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

373-381

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27834358%20AND%20SRC:MED&resulttype=core&format=json

CpG motifs: the active ingredient in bacterial extracts?

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Immunotherapeutic approaches to sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Spontaneous regression of tumour and the role of microbial infection--possibilities for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Effect of Bacillus Calmette-Guérin Infection on Transplanted Tumours in the Mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

An endotoxin-induced serum factor that causes necrosis of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Tumor immunity and autoimmunity induced by immunization with homologous DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Heteroclitic immunization induces tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Coupling and uncoupling of tumor immunity and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Definition of tumor antigens suitable for vaccine construction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Evolving Immunotherapy Approaches for Renal Cell Carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

The role of regional chemotherapy in the management of extremity soft tissue malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Immunotherapy for solid tumors--a review for surgeons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Resectability of Peritoneal Carcinomatosis: Learnings from a Prospective Cohort of 533 Consecutive Patients Selected for Cytoreductive Surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Peritoneal carcinomatosis of gastrointestinal tumors: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the american college of surgeons national surgical quality improvement program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Peritoneal surface oncology: review of a personal experience with colorectal and appendiceal malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Surgical management of bowel obstruction in patients with peritoneal carcinomatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: A systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

21 January 2018

Peritonectomy procedures

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Dendritic Cells: Features and Functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Systemic therapy for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Reversing T-cell Dysfunction and Exhaustion in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Oncolytic virus-initiated protective immunity against prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Safety and immunologic effects of IL-15 administration in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

7 January 2021

Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in the Management of Peritoneal Carcinomatosis

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

7 January 2021

Small intestinal obstruction from peritoneal carcinomatosis

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

7 January 2021

Adenocarcinoma of the sigmoid colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

7 January 2021

Pseudomyxoma peritonei. New concepts in management with a report of seventeen patients

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

7 January 2021

Pseudomyxoma peritonei

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

7 January 2021

Treatment of peritoneal carcinomatosis by continuous hyperthermic peritoneal perfusion with cisplatin.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

7 January 2021

Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

7 January 2021

Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

7 January 2021

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

7 January 2021

Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2016.49

7 January 2021

Malignant ascites: demographics, therapeutic efficacy and predictors of survival

1 reference

12 December 2020

A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.

1 reference

12 December 2020

Immunotherapy of malignant ascites with trifunctional antibodies

1 reference

12 December 2020

Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer

1 reference

12 December 2020

Implantation Peritoneal Carcinomatosis of Ovarian Origin.

1 reference

12 December 2020

A folate receptor-targeted lipoplex delivering interleukin-15 gene for colon cancer immunotherapy.

1 reference

12 December 2020

Immunodepression and malignancy

1 reference

12 December 2020

The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites

1 reference

12 December 2020

A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer

1 reference

12 December 2020

Dr William Coley and tumour regression: a place in history or in the future

1 reference

12 December 2020

The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression

1 reference

12 December 2020

Clinical delivery system for intraperitoneal hyperthermic chemotherapy.

1 reference

12 December 2020

Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors

1 reference

12 December 2020

Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer

1 reference

12 December 2020

Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma

1 reference

12 December 2020

Surgical palliation of small bowel obstruction due to metastatic carcinoma

1 reference

12 December 2020

Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma

1 reference

12 December 2020

Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective

1 reference

12 December 2020

Hyperthermic peritoneal perfusion system in canines

1 reference

12 December 2020

Comparison of the iv and ip routes of administration of cisplatin in dogs

1 reference

12 December 2020

The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893.

1 reference

12 December 2020

Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide

1 reference

12 December 2020

Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects

1 reference

12 December 2020